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Diabetes affects approximately 250 million people worldwide and health care 
costs related to diabetes equal approximately $98 billion each year. Aldose 
reductase has been shown to contribute to the side effects of diabetes 
including kidney disease, nerve disease, and retinopathy. Cranberries contain 
anthocyanins and other flavonoids that have been shown in vitro to inhibit the 
enzyme aldose reductase and to inhibit protein glycosylation. It is believed 
that daily cranberry supplementation could reduce side effects of diabetes. 
Twenty-seven adults with type 2 diabetes were recruited for this 12 week 
double-blind, placebo-controlled study. Fasting blood analysis was done at 
weeks 0, 6, and 12. The blood analyses included: cholesterol (total 
cholesterol, triglycerides, HDL, LDL, and percent HDL), glycosylated 
hemoglobin (HbA, c), blood glucose, insulin, fructosamine, aldose reductase 
activity, and hexanal. The subjects were asked to take 6 capsules each day 
that contained either spray-dried cranberry powder or a placebo. The placebo 
consisted of cellulose and artificial food coloring, as well as sucrose, fructose, 
magnesium hydroxide, and ascorbic acid in the same concentrations as in the 
cranberry powder. 
Improvements were seen in blood glucose levels, HbAic, fructosamine, 
insulin, total cholesterol, triglycerides, and percent HDL for some subjects. 
Glucose levels were significantly lower (p = 0.036) at week 12 in subjects who 
had diabetes more than 5 years in the cranberry group compared to the 
placebo group. At week 6, in subjects less than 50 years of age, blood 
glucose levels decreased significantly (p = 0.030) in the cranberry group 
compared to the placebo group. HbAlc levels decreased significantly (p = 
0.031) in the cranberry group at week 6 in subjects who had diabetes more 
than 5 years. Fructosamine levels improved significantly in patients less than 
age of 50 in the cranberry group compared to the placebo group from week 0 
to week 6 (p = 0.027). Triglyceride and total cholesterol levels were 
significantly lower (p = 0.013 and p = 0.007 respectively) in the cranberry 
group than the placebo group in subjects who had diabetes more than 5 
years. 
Cranberry supplementation may be beneficial for individuals with diabetes. 
More research is needed in subjects with poor glycemic control and to 
determine proper dosages. 
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INTRODUCTION 
BACKGROUND INFORMATION ON DIABETES MELLITUS 
The Expert Committee on the Diagnosis and Classification of Diabetes 
Mellitus (DM) defines diabetes as 'a group of metabolic disorders 
characterized by hyperglycemia resulting from defects in insulin secretion, 
insulin action or bothn (1). Insulin is a hormone that is produced by the beta 
cells of the pancreas and is necessary to utilize carbohydrate in the body. 
Insulin increases oxidation, glycogenesis (production of glycogen), and 
lipogenesis (production of fat from dietary carbohydrate), and helps to make 
possible the diffusion of glucose into cells of the body (2). There are many 
side effects associated with chronic hyperglycemia resulting from DM. The 
side effects include cardiovascular disease, macrovascular and microvascular 
disease, retinopathy, nephropathy, and neuropathy (1). Symptoms of DM 
indude significant weight loss, polyphagia (excessive hunger), polydipsia 
(excessive thirst), polyuria (excessive urination), and blurred vision (1, 2). 
TYPES OF DIABETES MELLITUS 
DM can be categorized as gestational DM, type 1 DM, type 2 DM, or other. 
The focus of this research project was type 2 DM. In gestational DM glucose 
intolerance occurs during pregnancy, and usually returns to normal after 
childbirth. Up to 60% of women with gestational DM will develop type 2 DM 
within 5 to 15 years (2). 
Type 1 DM, or insulin dependent DM, usually occurs at an early age (less 
than 30 years of age), however, the disease may occur at any age. In type 1 
DM there is autoimmune destruction of the beta cells of the pancreas, which 
halts insulin production. Glucose cannot be utilized without insulin, so glucose 
is excreted in the urine. Patients with type 1 DM experience significant weight 
loss, polyphagia, polydipsia, polyuria, and ketoacidosis (accumulation of 
ketone bodies due to excessive breakdown of fat). Exogenous insulin is 
necessary to prevent death in patients with type 1 DM (2). 
Approximately 97% of people with diabetes have type 2 DM, previously 
known as non-insulin dependent DM (3). Type 2 DM may occur at any age, 
but occurs most often in individuals over the age of thirty. Endogenous insulin 
secretion may be depressed, elevated, or normal, and there is a decrease in 
insulin sensitivity in the body. With a decrease in insulin sensitivity, more 
insulin is needed to control blood glucose levels in the body (2). The need for 
more insulin results in higher than normal levels of insulin in the blood in 
patients with type 2 DM. Type 2 DM has been linked to a sedentary lifestyle, 
poor nutritional habits, and being overweight (4); however, people who 
maintain a healthy weight may develop the disease. Individuals with type 2 
DM may or may not experience excessive hunger, thirst, and urination, and 
are unlikely to experience ketoacidosis (2). A patient may have type 2 DM for 
many years without being diagnosed because blood glucose levels may be 
elevated without causing symptoms severe enough to be noticed by the 
patient (1). The preferred treatment for type 2 DM is lifestyle change, which 
includes improved diet and exercise patterns. These changes are often 
difficult for patients to maintain, so drug therapy may become necessary. 
Oral medications that increase insulin secretion or improve insulin sensitivity 
may be prescribed when diet and exercise changes are not successful. Oral 
hypoglycemic drugs include sulfonylureas, meglitinides, biguanides, 
thiazolidinedione (TZDs), and alpha-glucosidase inhibitors. Sulfonylureas 
increase insulin production by stimulating the pancreas. Chlorpropamide, 
tolazamide, acetohedamide, and glipizide are examples of sulfonureas. 
Repaglinide is a meglitinide, which increases insulin production by stimulating 
the pancreas. Metformin (Glucophage) is a biguanide which increases insulin 
sensitivity and decreases liver production of glucose. Rosiglitasone (Avandia) 
and piog litazone (Actose) are TZDs which improve insulin sensitivity and 
improve carbohydrate metabolism. Precose and Glyset are alpha glucosidase 
inhibitors which work by decreasing glucose absorption in the small intestine 
(5). Type 2 DM may be treated with insulin in severe cases. Insulin therapy is 
not usually necessary for survival, but is necessary to control blood glucose 
levels and prevent side effects and complications of diabetes in approximately 
40% of patients (2, 6). 
DIAGNOSIS OF DIABETES MELLITUS 
Screening for DM may be completed if a person has risk factors for the 
disease, a family history of the disease, or shows symptoms of the disease. It 
is recommended that all individuals over the age of 45 be tested for diabetes 
every three years. According to the Expert Committee on Diagnosis and 
Classification of DM, there are three criteria for diagnosis of DM. The first is 
symptoms of diabetes with non-fasting plasma glucose greater than 200 
mg/dL (1 1.lmmollL). The second criteria for diagnosing DM is a fasting 
plasma glucose level greater than 126 mg/dL (7.0 mmoVL) (1, 6). This value 
was changed in 1998 from 140 mgldL (7.8 mmol1L) to 126 mgIdL (7.0 
mmol1L) in order to diagnose the disease earlier and prevent the many side 
effects and complications of the disease (6, 7). The third criteria for diagnosis 
of DM is a plasma glucose level greater than 200 mg1dL (1 1.1 mmol1L) two 
hours after an oral glucose tolerance test (1, 6). Elevation of blood glucose 
levels above 200 mg/dL (1 1.1 mmol1L) are associated with increased 
incidence of diabetic complications (7). 
COST OF DIABETES MELLITUS 
In 1997 there were approximately 124 million people worldwide that had been 
diagnosed with DM, and this number is increasing at an alarming rate (3). In 
the period from 1990 to 1998 there was a 33% increase in the number of 
Americans diagnosed with type 2 DM (4). With DM being diagnosed at 126 
mgldL instead of 140 mg1dL starting in 1998, the increased incidence of DM 
4 
likely continued since 1998. The increased incidence of obesity in the United 
States is a factor that likely contributed to the increased incidence of DM. 
Type 2 DM is being diagnosed at much earlier ages. As early as 10 years ago 
type 2 DM was a disease only found in adults, but at present as many as 
300,000 children in the United States have the disease (4). It is important to 
find a treatment to reduce the side effects of diabetes to decrease health care 
costs and improve quality of life for patients with DM. 
Persons with diabetes are three times more likely than nondiabetic persons 
to be hospitalized, which leads to increased healthcare costs (3). Risk of 
death is also higher in people with diabetes than non-diabetic persons (Table 
1 )- 
Table 1: Relative Risk of Death for People with DM 
- 
Risk Of Death 
[ ~ g e  45 - 64 1 4.4 times higher I 
Age 44 or younger 4.2 times higher 
Patients with DM have higher healthcare costs. Both direct and indirect costs 
Age 65 or older 
are problematic. Direct costs include physician visits, hospital stays, 
3 times higher 
medications, etc. Indirect costs include sick days, loss of income, loss of 
L 
(3) 
employment, and related expenses resulting from the disease (3). According 
to the National Institute of Health, total cost of diabetes in 1997 was $98 
billion. Direct medical costs were responsible for about $44 billion dollars and 
indirect costs were about $54 billion dollars (6). 
The American Diabetes Association evaluated the direct costs attributed to 
DM in the United States in 1997 (8). Sixty-two percent of expenditure for care 
of patients with DM was spent on inpatient care, 24.7% was spent on 
outpatient services and home health care, 12.5% was spent on nursing home 
care and 0.5% was spent on hospice care (Figure 1). 




 patl lent 
Care 
61% 
Researchers also found that expenditures for health care in people with DM 
increase as the patients age. Sixty-five percent of healthcare costs were for 
patients 65 years of age or older. Indirect costs are also higher in individuals 
with DM. Patients with DM lost an average of 8.3 days from work compared to 
1.7 days for individuals without diabetes. Results of this study indicate that 
health care costs are significantly higher for individuals with diabetes than for 
those who do not have the disease. 
Increased healthcare costs have been linked to increased glycosylated 
hemoglobin (HbAlc) levels (3). Serum HbAlc is an indicator of blood glucose 
control. A study by Gilmer et al. (9) investigated the cost of poor glycemic 
control for a Health Maintenance Organization (HMO). The subjects recruited 
for the study were all members of the HMO who had diabetes and were 
continuously enrolled in the HMO for the 4 year period of the study. 
Researchers found that when HbAlc levels were greater than 7%, healthcare 
costs increased 10% for each percent increase in HbAlc. Results of the study 
also indicated that in patients with heart disease and hypertension in addition 
to diabetes, there was a significant decrease in health care cost associated 
with a one percent decrease in HbA,c levels (Table 2). 
INTENSIVE TREATMENT VS TREATMENT OF COMPLICATIONS 
There are four major studies that have looked at the cost effectiveness of 
better blood glucose control compared to treating the complications that occur 
Table 2: Decreased Cost Associated with 1% Decrease in HbA,, Levels 
as a result of years of hyperglycemia. These studies include the Diabetes 
Control and Complications Trial (DCCT), Stockholm Study, the United 
Kingdom Prospective Diabetes Study (UKPDS), and the Kumamuto Study. 
Results of these studies suggest that intensive treatment of blood glucose 
levels costs more than traditional treatments, but reduce complications of DM. 
This leads to an overall cost reduction for DM patients with intensive 
treatment (3, 10) 
Decrease In HbA,, 
The DCCT (1 1, 12, 13) was a randomized clinical trial that compared the 
effects of conventional therapy to intensive therapy in patients with type 1 
diabetes. Fourteen hundred forty one subjects with type 1 diabetes were 
followed for approximately 6.5 years. Participants were divided into two 
groups; one group received conventional therapy and the other intensive 
therapy. Subjects in the group receiving conventional therapy received one or 
two insulin injections daily. Patients receiving intensive therapy received three 
Cost Savings Per Year 
or more insulin injections daily to maintain blood glucose levels as close to 
normal as possible. Results of the study indicated that subjects in the 
intensive treatment group had significantly lower average HbAic levels than 
the group receiving conventional treatment. This indicates that overall blood 
glucose levels were significantly lower in the intensively treated group. There 
was a 54% decreased risk of developing retinopathy with intensive treatment 
than conventional treatment. Risk of developing microalbuminemia (protein 
loss in the urine) decreased 34% with intensive treatment. At five years, the 
risk of developing neuropathy was decreased by 69% with intensive treatment 
when compared to conventional treatment. Results of this study indicated that 
there is a decrease in side effects and complications of diabetes when blood 
glucose levels are more tightly controlled (1 1, 12, 13). 
In 1998, Turner published a review on the results of the UKPDS (14). The 
main objective of the UKPDS was to determine if intensive control of blood 
glucose levels in patients with DM would reduce risks for the side effects and 
complications of DM. Five thousand one hundred two patients with type 2 DM 
were recruited to participate in the study. Fifty percent of the subjects had 
signs of tissue damage related to diabetes at the beginning of the study. 
Initially all patients received diet therapy. The subjects were then randomized 
into one of four treatment groups. One group was treated with conventional 
therapy with dietary treatment, another group received intensive treatment 
with chlorpramide, another group received intensive treatment with glyburide, 
and the final group received intensive insulin therapy. An additional group of 
obese individuals received metformin. In all intensive treatment groups the 
goal of therapy was to achieve fasting glucose levels less than 108 mg/dL. 
Results indicated that intensive treatment was successful in lowering blood 
glucose concentrations, and that all methods of intensive therapy tested were 
equally effective in controlling blood glucose levels. Intensive treatment of 
diabetes can decrease blood glucose levels, which will decrease side effects 
and complications of the disease (14, 15). 
ACCOMPANYING CONDITIONS 
There are many complications associated with development of DM including: 
cardiovascular disease, stroke, neuropathy, nephropathy, and retinopathy 
(16). The UKPDS has shown a reduction of microvascular complications 
associated with DM, and a reduction of myocardial infarction with increased 
control of blood glucose levels (16). 
Cardiovascular Disease 
Diabetes increases a patient's risk of developing heart disease. A man with 
diabetes has double the risk of developing heart disease than a man without 
the disease, and a woman with diabetes has four times greater risk of death 
than a woman without the disease (4,7). The number one cause of death 
among people with diabetes is cardiovascular disease (CVD). Diabetes is an 
independent risk factor for CVD (4). Up to 80% of individuals with type 2 DM 
will die from CVD (1 7). 
The San Antonio Heart study, conducted by Wei et al. (18) was a 7 to 8 year 
study investigating the effect of hyperglycemia on risk of developing CVD in 
4,875 subjects. At baseline there were 471 subjects with diabetes and 4,404 
non-diabetic subjects. An additional 27% of subjects developed diabetes 
during the follow-up period. Researchers found that hyperglycemia is an 
independent risk factor for CVD, and that risk for CVD increases as blood 
glucose levels increase. It was also noted that TG levels increased and HDL 
cholesterol decreased with increased plasma glucose levels. 
Turner et al. (19) analyzed data from the UKPDS for risk factors for coronary 
artery disease (CAD) related to diabetes. Results indicated that risk factors 
for CAD were elevated levels of LDL cholesterol, triglycerides, HbAlc, fasting 
plasma glucose, and systolic blood pressure, and low levels of HDL 
cholesterol. There was a 1.57 fold increase in risk for CAD with each 1 
mmoVL increase in LDL cholesterol and a 0.1 5-fold decrease in risk for CAD 
with each 0.1 mmolIL increase in HDL cholesterol. This study also found an 
11% increase in risk of CAD for each 1% increase in HbAlc. 
Oxidation of LDL is a causative factor of atherosclerosis (20). It is believed 
that antioxidants may have a protective effect and reduce the oxidation of 
LDL. Flavonoids are antioxidants, and it has been shown that there is an 
inverse relationship between intake of dietary flavonoids and coronary heart 
disease (20, 21). 
Neuropathy 
Neuropathy is damage to the nervous system caused by chronic 
hyperglycemia (22). Approximately 60 to 70% of people with diabetes have 
some degree of neuropathy. Neuropathy may lead to impaired sensation in 
the hands or feet, which can result in foot ulcers and amputation of 
extremities. In the United States more than 50% of lower limb amputations 
are the result of diabetes, with approximately 67,000 amputations being 
performed yearly on people with diabetes. Autonomic neuropathy may lead to 
gastrointestinal, genitourinary, cardiovascular or sexual dysfunction (1, 6, 23). 
Symptoms of neuropathy include tingling or numbness in the extremities, 
decreased ability to feel hot or cold, and impaired reflexes (23). 
In a study published in 1997, Adler et al. (23) investigated risk factors for 
diabetic peripheral sensory neuropathy. Subjects included 778 U.S. veterans, 
of which 78% were white and 98% were male. Monofilament testing was used 
to determine presence of neuropathy. Patients were tested at baseline and 
were followed up within 2 to 3 years. Results indicated that height, age, HbAlc 
level, and history of lower-extremity ulcer are all independent risk factors for 
diabetic neuropathy. 
Nephropathy 
The primary cause of renal failure is DM. Approximately 10% of people with 
renal failure has diabetes (24), and diabetes is responsible for approximately 
40% of new cases of end-stage renal disease (6). Several factors may be 
responsible for nephropathy in patients with DM. Oxidative stress may 
damage the kidneys due to the increase in reactive oxygen species 
associated with hyperglycemia and glycosylation of proteins (25). A high 
concentration of aldose reductase in the inner medulla of the kidney leads to 
the buildup of sorbitol, which can damage the kidneys (26). Many patients 
with type 2 DM have high blood pressure, which increases stress on the 
kidneys. Table 3 lists the stages in the progression of diabetic kidney disease. 
Table 3: Stages of Nephropathy 
P 











Clinical Albuminemia Increased amounts of albumin and 




End Stage Kidney 
Disease 
Decreased glomerular filtration rate 
( ~ 7 5  muminute) 
Glomerular filtration rate c10 
muminute 
Retinopathy 
Diabetic retinopathy is a side effect of both type 1 and type 2 DM, and risk of 
developing diabetic retinopathy increases with duration of the disease (28) 
Diabetic retinopathy is the leading cause of blindness in adults and is 
responsible for 12,000 to 24,000 new cases of blindness each year (6). Early 
characteristics of retinopathy include macroaneurisms (ballooning out of walls 
of blood vessels), hemorrhages, and hard exudates (leakage of proteins and 
lipids from the blood into retina). There are several mechanisms that lead to 
diabetic retinopathy. The first is macular edema or fluid in the retina, which 
results from buildup of hard exudates. The second is growth of new blood 
vessels on the retina. The third is hemorrhaging from capillaries into the eye 
(28). 
Cataracts also lead to vision deficits in patients with DM. There is a high 
concentration of aldose reductase in the lens of the eye; therefore, when 
blood glucose levels are elevated, sorbitol accumulates in the lens. The high 
concentration of sugar alcohol causes water to be pulled into the lens, which 
leads to vision deficits. Inhibition of the enzyme aldose reductase may reduce 
the vision impairments caused by DM. 
LINK BETWEEN DIET AND DIABETES MELLITUS 
The increase in incidence of type 2 DM is likely due to changes in dietary 
habits. There have been numerous studies looking at the dietary habits of 
patients with type 2 DM (29,30,31). A decline in consumption of whole grains, 
fruits, and vegetables and an increase in consumption of highly processed 
convenience foods and high fat fast food have been shown to increase risk 
for developing type 2 DM. 
Uusitupa et al. (32) investigated the effect of diet and exercise in preventing 
or delaying onset of type 2 DM in patients with impaired glucose tolerance 
(IGT) in the Finnish Diabetes Prevention Study. Five hundred twenty three 
subjects with IGT were recruited for this ongoing controlled trial. The 
treatment group was counseled to improve diet and exercise habits. The 
advised diet contained greater than 50% of kcals from carbohydrates, less 
than 30% from fat, less than 300 mg of cholesterol, and at least 15 grams of 
fiber per day. After 1 year, subjects in the treatment group had significantly 
lower 2 hour glucose levels, fasting glucose levels, and 2 hour insulin levels 
than the control group. Results of this study suggest that there is a decreased 
risk of developing type 2 DM with changes in diet and exercise habits. 
Ford and Mokdad (33) investigated whether consumption of fruits and 
vegetables had a preventive effect for DM. Researchers followed 9,665 
subjects for approximately 20 years, and mean daily intake of fruits and 
vegetables was recorded. Results indicated that the mean number of fruits 
and vegetables eaten daily was lower in the group that developed DM. There 
was also a lower percentage of people who consumed 5 or more servings of 
fruits and vegetables daily in the group that developed DM. 
A study published in 2002 by van Dam et al. (29) looked at the association 
between dietary intake and risk for developing type 2 DM. This study was a 
prospective cohort study in which 42,504 professional men were followed for 
12 years (1 986 to 1998). A food frequency questionnaire was given every 4 
years and was used to determine foods commonly eaten by subjects, portion 
sizes consumed, and how often specific foods were consumed. Every 2 years 
participants were given a questionnaire about "exposures and newly 
diagnosed diseases." Subjects were grouped into one of two dietary patterns, 
either prudent or western. The prudent dietary pattern was characterized by a 
high consumption of whole grains, fruits, vegetables, and fish. The western 
dietary pattern was characterized by a high consumption of red meat, 
processed meat, French fries, high fat dairy products, sweets and desserts, 
and refined grains. Results of this study indicated that the risk of developing 
type 2 DM increased in participants with the western dietary pattern, and 
decreased with consumption of the prudent dietary pattern. 
A study conducted by Ekblond et al. (31) looked at the effects of dietary 
intake on urinary glucose excretion, which is a predictor of type 2 DM. The 
cross-sectional study took place between December 1993 and April 1997, 
and 27,146 Danish men and 29,861 women participated in the study. All 
participants filled out a food frequency questionnaire and a lifestyle 
questionnaire with questions about smoking, alcohol intake, physical activity 
and medical history. Subjects who experienced urinary glucose excretion 
during the study were compared to subjects who did not. Investigators found 
that persons with glucosuria tended to eat more meat and less fruits and 
vegetables, cereal grains, and poultry than subjects who did not experience 
glucosuria. 
Control of blood glucose levels can be monitored by measuring blood glucose 
concentrations, fructosamine levels or glycosylated (glycated) hemoglobin 
(HbAlc) levels. Measurement of serum glucose levels is an indication of 
current blood glucose control (1). The fructosamine assay measures 
glycosylated albumin or glycosylated total proteins. According to Arrnbruster 
(34), fructosamine is a "ketoamine" which is produced by a non-enzymatic 
reaction between a sugar and a protein. The sugar is normally glucose and 
the protein normally albumin. Measurement of fructosamine levels is an 
indicator of blood glucose control in the 2 to 3 weeks prior to the test (34). 
Glycosylated hemoglobin is a hemoglobin protein that a glucose molecule has 
covalently attached itself to. These proteins are more susceptible to oxidative 
damage than normal hemoglobin molecules. Serum HbAlc levels are an 
indication of blood glucose control in the previous 3 months. Because the life 
span of a red blood cell is 3 months, it takes this long for all of the hemoglobin 
molecules in the body to turnover. HbAlc and fasting glucose tests are the 
methods that are currently recommended to monitor treatment of diabetes by 
the Expert Committee on the Diagnosis and Classification of Diabetes 
Mellitus (1). Treatment goals for individuals with type 2 DM are listed in Table 
4. 
Table 4: Methods of Monitoring Treatment of DM 
Indicator 
Blood glucose levels 
PROTEIN GLYCOSYLATION 
Presence Of Hyperglycemia 
Serum Fructosamine 
Serum HbA,, 
Protein glycosylation (or glycation) is a direct non-enzymatic reaction between 
a reducing sugar and the amino group of a protein (36). This is a non- 
enzymatic reaction where the glucose molecule covalently attaches itself to a 
reactive amino group. The rate at which this reaction occurs is dependent on 
blood glucose concentrations. These glycated proteins are precursors to 
advanced glycation products. Non-enzymatic glycation of proteins is also 
damaging to the body because this increases the rate of free radical 
production 50-fold (37). 
Normal Values 
Immediate 3.9 to 7.0 mmoVL 
(1, 35) 
Previous 2 to 3 weeks 
Previous 3 months 
1.6-2.6 mmolIL 
Less than 6% 
Many proteins in the body experience glycosylation when blood glucose 
levels are elevated. Proteins susceptible to protein glycosylation include 
hemoglobin, red blood cell membrane proteins, albumin, collagen, myelin, 
and proteins in the lens of the eye. Protein glycosylation is an oxidation 
reaction; therefore, it is believed that antioxidants are effective in preventing 
this reaction (36). 
ALDOSE REDUCTASE 
Aldose reductase is known to be the cause of many of the complications of 
type 2 DM including cataracts, retinopathy, nephropathy, and neuropathy. 
Aldose reductase is an enzyme found in the body that is responsible for the 
reduction of glucose to sorbitol in the polyol pathway (Figure 2) (37). This 
reaction occurs when D-glucose is converted to sorbitol by aldose reductase. 
This pathway is only active when blood glucose concentrations are elevated 
(38). Hexokinase is an enzyme that converts glucose to glucose-&phosphate. 
Glucose-6-phosphate is the form of glucose that is used by the cells of the 
body. When hexokinase becomes saturated due to hyperglycemic conditions, 
aldose reductase is activated to convert excess glucose to sorbitol. Sorbitol 
cannot be used in the body as a fuel source, so it needs to be converted to 
something useable. The enzyme sorbitol dehydrogenase converts sorbitol to 
fructose; however, concentrations of sorbitol dehydrogenase do not increase 
in proportion to concentrations of sorbitol, so sorbitol builds up in the tissues. 
The fructose that is converted from sorbitol may also damage proteins due to 
enzymatic fructosylation of proteins. The fructose may be converted to 3- 
deoxyglucosone, which is a precursor to advanced glycation end products. 
This pathway also leads to production of free radicals for autoxidation of 
glucose, hydrogen peroxide (H202), and superoxide molecules (02.) (37). 
Figure 2: Polyol Pathway 




If an increase in aldose reductase is responsible for many of the side effects 
of diabetes, including neuropathy, nephropathy, and retinopathy, then finding 
a way to inhibit this enzyme may decrease the side effects of DM and 
improve quality of life for people with DM (36). 
Hexokinase ucose-SPhosphate 
In a study published in 2002, Obrisiva et al. (39) investigated the effect of 
sorbinil, an aldose reductase inhi bitor, on rat peripheral nerve function, 
metabolism and antioxidant defense. When a dose of 65 mglkg of body 
weight of sorbinil was given, there were significant improvements in 
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neurovascular function and nerve conduction. An improvement in metabolic 
abnormalities was also noted. Lipid peroxidation was increased in diabetic 
rats compared to the control group, but the lipid peroxidation was arrested 
with administration of sorbinil. 
Hamada et al. (40) investigated the effect of epalrestat, a known aldose 
reductase inhibitor, on the accumulation of end products of glycation. Blood 
was drawn from 38 subjects with type 2 DM. Sixteen of the subjects had been 
taking 150 mg of epalrestat daily for 2 months and 38 had not been treated 
with the drug. Sorbitol, fructose, trig lycerides, carboxymethyl-lysine (CML), 
triosephosphates, erythrocyte 3-deoxyglucosone (3-DG), and the 
thiobarbituric acid-reactive substance (TBARS) assay were measured. 
TBARS are products of the decomposition of hydroperoxides. Sorbitol and 
fructose are products of the polyol pathway, and CML, triosephosphates, 3- 
DG are advanced glycation end products. Results indicated that sorbitol, 
fructose, triosephosphates, TBARS and 3-DG levels were significantly lower 
in subjects receiving epalrestat than in patients not receiving the drug. There 
were no changes in plasma glucose or HbAlc levels. These results suggest 
that inhibition of the enzyme aldose reductase can reduce the end products of 
protein glycosylation. 
A study conducted by Vincent et al. (38) investigated the ability of vitamin C to 
inhibit aldose reductase. Human erythrocytes collected from normal 
volunteers were used for the study. The erythrocytes were incubated with 
increasing concentrations of glucose from 5 to 40 mM, and sorbitol 
concentrations increased progressively with the increasing concentrations of 
glucose. Ascorbic acid was then added and was found to decrease 
intracellular sorbitol concentrations by 25 to 45 %. 
Pfeifer et al. (22) conducted a review of research completed investigating the 
efficacy of aldose reductase inhibitors (ARI) on the side effects of diabetes. Of 
32 clinical trials on the effect of ARI on distal symmetrical polyneuropathy, 
59% showed positive results on at least one measure. Most often motor nerve 
conduction velocity was improved by treatment with an ARI. Of 15 trials 
conducted on the effect of ARI on autonomic neuropathy, 5 showed 
improvement in autonomic neuropathy. These trials indicate that ARI may be 
a promising treatment to reduce side effects in patients with DM, but due to 
the number of studies that have not shown positive results, more research 
needs to be completed. 
ALTERNATIVE TREATMENTS 
Use of complementary and alternative medicine (CAM) has become popular 
recently for treatment and prevention of disease. CAM is defined as use of 
therapies and treatments that are not used in conventional medicine (41). 
Several research studies have investigated the used of CAM in treatment of 
diabetes. 
Egede et al. (41) analyzed data collected in the Medical Expenditure Panel 
Survey (MEPS) conducted in 1996. The MEPS collected data on CAM use, 
medical conditions, health insurance, demographic information, and health 
care expenditures for US citizens. Egede et al. analyzed data on 
demographics, medical conditions and CAM use. Results of the survey 
indicated that patients with DM were more likely to use CAM than patients 
with no chronic diseases. The CAM therapies most often used by patients 
with DM were nutritional advice, spiritual healing, herbal remedies, massage 
therapy, and meditation training. 
Ryan et al. (42) conducted a survey investigating the use of CAM in patients 
with diabetes. Five hundred two patients with diabetes and 201 nondiabetic 
control subjects were surveyed. Results indicated that 78% of patients with 
DM were taking prescription medications compared to 63% of non-DM 
patients. When use of over-the counter supplements (OTCS) were compared, 
researchers found that 44% of patients with DM compared to 51% of non-DM 
patients were taking OTCS. Thirty-one percent of patients with DM were 
using CAM compared to 37% of non-DM subjects. CAM supplements used by 
subjects with DM included garlic, Echinacea, glucosamine, chromium, ginkgo 
biloba, cayenne and St. John's Wort. Only patients with DM reported taking 
chromium, which is believed to improve blood glucose control. Researchers 
also found that patients with DM spent approximately the same amount on 
over-the-counter supplements and alternative medicine as they did on 
prescription medications ($23.53 per month for OTC and CAM supplements 
compared to $28.51 for prescription medications). Subjects with DM used 
CAM supplements and OTCS in addition to prescription medications, rather 
than replace prescription medications with CAM supplements and OTCS. 
ANTHOCYANINS AND FLAVONOIDS 
Anthocyanins and flavonoids are chemicals found in fruits, vegetables, nuts, 
seeds, stems, flowers, tea, and wine that are powerful antioxidants. These 
compounds have been shown to improve resistance of LDL to oxidation, 
protect against oxidative damage, decrease protein glycosylation and affect 
enzyme activity (36). Fresh berries are a rich source of flavonoids and 
anthocyanins. Lipid oxidation is believed to be a causative factor in 
cardiovascular disease. Antioxidants, such as anthocyanins and flavonoids 
found in fruits and vegetables, can help protect against lipid oxidation and 
therefore protect against cardiovascular disease. 
Protein Glycosylation 
Camire et ai. (43) investigated the ability of fruit anthocyanins to inhibit aldose 
reductase in-vitro. Fruit powders of raspberries, blueberries, cranberries and 
grapes were analyzed as well as the flavonoid quercetin and anthyocyanin 
aglycones cyanidin, delphinidin and malvidin. Aldose reductase was inhibited 
10 to 52% by fruit powders. Raspberries were most effective at inhibiting 
aldose reductase followed by blueberry and cranberry powders. Grape 
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powder was the least effective inhibitor of aldose reductase. Over 90% of the 
aldose reductase was inhibited by quercetin, cyanidin and delphinidin, and 
only 70% was inhibited by malvidin. 
Keenoy and De Leeuw (44) investigated the effect of Daflon, a flavonoid 
preparation containing 90% diosmin and 10% hesperidin, on protein 
glyosylation and antioxidant status. Twenty-eight subjects with type 1 DM 
participated in the 3-month double-blind, placebo-controlled study. Blood 
glucose and HbAic levels were measured to determine blood glucose control 
and protein glycosylation. Antioxidant capacity was measured by determining 
reduced glutathione (GSH) and gluthione peroxidase content in red blood 
cells. Blood glucose levels remained constant during the course of the study, 
but HbAlc levels decreased significantly with flavonoid treatment. No 
significant differences in antioxidant activity were found between the flavonoid 
group and the placebo group. 
Asgary et al. (36) conducted a study which looked at the effect of the 
flavonoids quercetin, rutin, and kaempherol on protein glycosylation in vitro. 
The optimal concentration and incubation time of flavonoids to reduce protein 
glycosylation was investigated. A colorimetric method was used to determine 
the degree of hemoglobin glycosylation in the presence of each flavonoid. 
Results of the study indicated that all three of the flavonoids had a preventive 
effect on protein glycosylation (Table 5). The preventive effect of the 
flavonoids on protein glycosylation was dependent on the concentration of the 
flavonoid. Quercetin had the greatest effect on protein glycosylation and 
kaempherol had the least effect. Additional studies need to be completed to 
determine whether flavonoids have the same effect on protein glycosylation in 
vivo (36). 
Table 5: Inhibition of Hemoglobin Glycosylation by Flavonoids 





In 2000, a study by Jankowiski et al. (45) investigated the effects of 
anthocyanin pigments from red wine on diabetes. The study used 80 rats 
divided into 4 groups: a control group, a group receiving streptozotocin to 
induce diabetes, a group receiving intragastric anthocyanins, and a group 
receiving streptozotocin and anthocyanins. Glucose concentrations in blood 
and urine increased in the rats after streptozotocin was injected, but was 
decreased in the animals receiving anthocyanins. There was a substantial 
decrease in blood and urine glucose, a reduction in free radical production 







oxidation in blood and urine in the group of rats receiving streptozotocin and 
anthocyanins. 
Lipid Oxidation 
In 1997 Laplaud et al. (20) conducted a study looking at the antioxidant effect 
of blueberry extract on human LDL in vitro. Plasma was obtained from 6 
fasting adult Caucasians, and the LDL was isolated by ultracentrifugation. 
Copper chloride was used to induce LDL oxidation. A lipoperoxide assay, a 
TBARS assay, and relative electrophoretic mobility (REM) were performed on 
the LDL to determine the amount of oxidation with the addition of differing 
amounts of blueberry extract. The results indicated that the blueberry 
antioxidants are effective in inhibiting the oxidation of LDL at concentrations 
as low as 15 pg1mL. 
In 1998, Heinonen et al. (46) conducted a study looking at the effect of 
polyphenolics found in berries on oxidation of LDL and liposomes. The berries 
chosen for this study included blackberries, red raspberries, sweet cherries, 
blueberries, and strawberries. In this study LDL oxidation was completely 
inhibited by all berries except strawberries and blueberries. Berry extracts 
were successful in inhibiting 27 to 68% of hydroperoxide formation and 60.5 
to 92.6% of hexanal formation. 
In 1999, Gabrielska et al. (47) conducted a study looking at the effect of 
anthocyanin pigments extracted from chokeberry, honeysuckle and sloe on 
lipid oxidation in vitro. Lipid oxidation was induced in the liposome membrane 
by ultraviolet radiation. The amount of oxidation was evaluated by a TBARS 
assay. HPLC was used to evaluate the end products of lipid membrane 
oxidation. The results of this study indicated that the anthocyanins found in 
chokeberry, honeysuckle and sloe are protective against free radical oxidation 
of the lipid membrane. 
Many research studies have been completed investigating the effect 
anthocyanins and flavonoids have on DM. The results indicate that these 
compounds have a protective effect on lipid oxidation and protein 
glycosylation in vitro. More research needs to be completed to determine if 
the same effects occur in vivo. 
CRANBERRIES 
Cranberries (Vaccinium macrocarpon) have been believed to be useful to 
prevent disease and treat illness for hundreds of years. Native Americans 
used cranberries to treat wounds and blood poisoning, and American sailors 
ate cranberries to prevent scurvy. The leaves of the cranberry plant have 
been used to treat diarrhea, urinary disorders and diabetes. Most research 
has been focused on the ability of cranberry juice to prevent and treat urinary 
tract infections (48). Cranberries are widely used as a treatment for urinary 
tract infections, even though conclusive documentation has not been 
published. 
Composition 
In a study published in 2001, Prior et al. (49) analyzed the anthocyanin 
content of blueberries and cranberries. Researchers found that the four major 
anthocyanins that are responsible for the red color of cranberries are 
cyanidin-3-galactoside, peonidin-3-galactwide, cyanidin-3-arabinoside, and 
peonidin-3-arabinoside. Cranberries also contain smaller amounts of the 
anthocyanin cyanidin-3-glucoside and peonidin-3-glucoside (Table 6). 
Table 6: Percent of Anthocyanins found in Cranberries 
~nthoc~anins I % Of Total Anthocyanins 
I Peonidin-3-ara binoside 15.8 
In an article published in 2001, Kahkonen et al. (50) reported the phenolic and 
anthocyanin content of berries and apples. Cranberry ( Vaccinium oxycoccus) 
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samples were extracted by acetone extraction and then dried and frozen for 
up to 1 week before being analyzed. The cranberries contained 397 mg of 
anthocyanins per 1009 of dry weight of cranberries. The flavonoid content of 
the analyzed sample was 200 mgl100g dry weight. 
Hakkinen et al. (51) investigated the content of the flavonoids quercetin, 
myricetin and kaem p hferol in berries including cranberries. Vaccinium 
oxycoccos, a species of wild cranberry, was used in this study. Researchers 
found large amounts of quercetin (83 to 121 mglkg) and myricetin (74 to 142 
mglkg) in the cranberry samples, but kaemphferol was not found. Cranberry 
had the second highest total flavonoid content (157 to 263 mglkg) of the 
bemes analyzed, second only to bog whortleberry (1 84 mglkg). 
Bioactivity of Cranberry Components 
Pedersen et al. (52) conducted a study comparing the antioxidant capacity of 
cranberry and blueberry juice in the plasma of nine female volunteers. 
Researchers used ferric reducing antioxidant value (FRAP value) as one 
measure of plasma antioxidant activity, and electron spin resonance 
spectroscopy (ESR) to determine the ability of the plasma to donate a 
hydrogen atom or electron to a free radical. Results indicated that 
consumption of blueberry juice did not significantly increase concentrations of 
total phenols or vitamin C in the plasma of the volunteers. Researchers 
question how readily the phenols are absorbed in the gut. Consumption of 
cranberry juice did lead to significant increases in total phenols and a 30% 
increase in serum vitamin C concentration. Researchers question if the 
increase of total phenols in serum following cranberry juice consumption is 
primarily due to the increased vitamin C levels. 
Wilson et al. (53) conducted a study looking at the ability of cranberry extract 
to protect against low density lipoprotein oxidation. LDL was separated from 
the serum of 5 male volunteers and used for the study. Oxidation of the LDL 
samples was promoted and cranberry extract was added to each sample at 
concentrations of 0.00%, 0.10%, 0.010%, or 0.005%. After incubation, the 
samples were tested for oxidation by TBARS and electrophoresis. Results 
indicated that TBARS were inhibited at a 0.10% dilution and electrophoretic 
movement was reduced significantly when up to 0.05% dilution of cranberry 
extract was used. In this study cranberry inhibited LDL oxidation in-vitro. 
Wang and Jiao (54) investigated the protective effect of cranberries, 
blackberries, blueberries, raspberries, and strawberries against superoxide 
radicals (0;-), hydrogen peroxide (H202), hydroxyl radicals (OH), and singlet 
oxygen (02). Researchers found that the ability to inhibit oxidation by these 
radicals varied by cultivars, but all cranberries tested inhibited greater than 
54% of 0;-, greater than 55% of H202, greater than 59% of OH, and greater 
than 7% of 02. 
There has been a great deal of research investigating the effects of cranberry 
anthocyanins and flavonoids in vitro. It is possible that cranberry 
supplementation may decrease the protein glycosylation and lipid oxidation 
that contribute to the side effects of DM. The anthocyanins and flavonoids in 
cranbeny may inhibit the enzyme aldose reductase, and therefore may inhibit 
the buildup of sorbitol in tissues of the body. 
MATERIALS AND METHODS 
STUDY DESIGN 
Twenty-seven adults with type 2 DM, controlling their disease with diet and 
exercise, were recruited for this twelve week, double blind, placebo controlled 
study. Subjects were recruited from ads placed in the Bangor Daily News and 
in the Maine Perspective. Fliers were put up at local stores and health clubs, 
and notices were posted on the First Class University of Maine computer 
conference. Patients taking oral medications or insulin to control blood 
glucose levels were not invited to participate in the study. The University of 
Maine Protection of Human Subjects Review Board approved the study. 
Subjects were randomly assigned to either the cranberry group or the placebo 
group. Participants were asked to fill out an informed consent form (Appendix 
A), a health history questionnaire (Appendix B), and a food frequency 
questionnaire (Appendix C) at the first blood draw. Instructions were provided 
on the front page of the questionnaires, and someone was available to 
answer questions while subjects were filling out the questionnaires. During 
the study, participants were asked to take 6 capsules daily filled with either 
the cranberry powder or the placebo, and have blood drawn at 0, 6, and 12 
weeks (Figure 3). Blood samples were taken after an overnight fast. A stipend 
of $50 dollars was given to each subject after each of the three blood draws 
for a total of $150. 
Figure 3: Study Design 
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CRANBERRY TREATMENT 
Size 00 gelatin capsules (00-coni-shape) (Feton Chemical and 
Pharmaceutical Company, Ramsey, NJ) were filled with Decas Cranberry 
Juice Concentrate Powder 90 (product code 06054), which was generously 
provided by Decas Cranberry Products (Wareham, MA). A Feton model 101 
capsule filling machine was purchased from Feton Chemical and 
Pharmaceutical Company (Ramsey, NJ). 
The capsules were opened by the filling machine, and were then filled with 
the powder. The powder was tamped down three times to ensure that the 
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capsules were filled completely. The machine then closed the capsules. Ten 
empty capsules were weighed with a Sartorius Analytical balance (model 
A2005, Sartorius Corporation, Edgewood, NY), and the total was divided by 
10 to get the average weight of one capsule. The weight of an empty capsule 
was 0.12 grams. The average weight of the filled capsules was 0.64 grams. 
Each capsule of cranberry powder contained approximately 0.53 grams of 
Decas Cranberry Juice Concentrate Powder 90. The cranberry powder is 
90% cranberry juice, so the weight of actual cranberry juice in each capsule is 
0.48 grams. 
The subjects in the treatment group were given cranberry capsules that 
contained the equivalent of eight ounces (240 mL) of cranberry juice cocktail, 
since that beverage is the major form of cranberry consumed in the United 
States. To calculate the amount of cranberry powder each subject needed 
daily, it was first important to know that liquid commercial cranberry juice 
cocktail contains approximately 27% cranberry juice. The Decas Cranberry 
Juice Concentrate Powder 90 is 90% cranberry juice. Nutrition information 
from Nutritionist 5 Nutrient Database (First DataBank, San Bruno, CA) was 
used to calculate the amount of cranberry in commercial juice. Each 8 ounce 
serving of cranberry juice cocktail weighs 253 grams. There are 216 grams of 
water and 34.2 grams of sugar in each 253-gram serving of juice. The water 
and sugar in the juice were subtracted from the total weight; 2.8 grams of 
cranberry juice are present in each 8 ounce serving of cranberry juice. The 
cranberry powder is 90% cranberry juice, so the weight of cranberry powder 
in each capsule (0.53 grams) was multiplied by 90% to get the amount of 
cranberry juice in each capsule (0.48 grams). With 0.48 grams of actual 
cranberry juice in each capsule, six (5.89) cranberry capsules were required 
to equal an eight ounce serving of cranberry juice. Table 7 displays the 
nutritional information for cranberry powder. 













L I I 
Nutrition information provided by Decas Cranbeny Products Wareham, MA. 
2.1 mg 
Magnesium 
SUGAR ANALYSIS OF CRANBERRY POWDER 
183.4 mg 
High performance liquid chromatography (HPLC) analysis was performed on 
the Cranberry Juice Concentrate Powder 90 using a Hewlett Packard HP 
3394 Integrator (Palo Alto, CA), a Waters Associates Differential 
Refractometer, model R401 (Milford, MA), a Shimadzu LCO6A isocratic pump 
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(Braintree, MA), a Primesphere NH2, 5p, 250 x 4.6 mm HPLC column 
(Phenomenex Inc. Torance, CA), and a VlCl model E 60 injector (Valco 
Instruments Co Inc. Houston, TX). Acetonitrile (HPLC grade, A998-4) and 
water (HPLC grade, W5-4) for the HPLC analysis were purchased from EM 
science (Gibbstown, NJ). SIGMA ultra fructose (F2543) and sucrose (51 174) 
were purchased from SIGMA Chemical Company (St Louis, MO). Anhydrous 
dextrose (D16-500) was purchased from TT Baker Chemical Company 
(Phillipsburg NJ). 
High-performance liquid chromatography was used to determine the 
percentage of glucose and fructose in the Decas Cranberry Juice 
Concentrate Powder 90. This information was necessary to ensure that the 
placebo contained the same concentrations of glucose and fructose as the 
treatment. The mobile phase was 75% acetonitrile and 25% water, and a flow 
rate of 1.5 mL per minute was used. Five grams of Decas Cranberry Juice 
Concentrate Powder 90 was mixed with enough ethyl alcohol (ETOH) to 
make a 50 mL solution. The standard was mixed using 0.0786 grams of 
fructose, 0.0782 grams of dextrose, 0.0743 grams of sucrose and enough 
85% ETOH to bring the solution up to 100 mL. Twenty-five pL of standards 
and sample solutions were injected into the HPLC system. The 
chromatogram of HPLC sugar analysis of cranberry powder is located in 
Appendix D. 
The following equation was used to calculate the amount of each sugar per 
mg of cranberry powder: 
Glucose = (peak heiaht-sample (cml \ x (conc of std mg1mL) x (50m~ (total volume of sarnplel\ 
or fructose \ peak height-std (cm) 1 \ 0.5 grams (sample wt) 1 
conc = concentration std = standard wt = weight 
The average of two analyses was used to determine the percentage of 
glucose and fructose in the Cranberry Juice Concentrate Powder 90. 
PLACEBO 
To ensure that any results were an effect of the cranberry powder and not the 
concentration of sugar, magnesium or ascorbic acid, it was important to 
ensure that the placebo contained the same concentrations of glucose, 
fructose, magnesium hydroxide, and ascorbic acid as the cranberry 
treatment. HPLC analysis of the Decas Cranberry Juice Concentrate Powder 
90 indicated that each gram of the powder contained 57.6 mg (6%) of 
fructose and 184.2 (18%) mg of glucose. The Decas Cranberry Juice 
Concentrate Powder 90 is processed using magnesium hydroxide. Each 
gram of the cranberry powder contains 61.13 mg (6%) of magnesium. The 
Decas Cranberry Juice Concentrate Powder 90 contains 1 mg of ascorbic 
acid per gram of powder, which makes it 0.1 % ascorbic acid. 
A total of 4000 grams of the placebo powder was made. Purified cellulose 
(grade: just fiber, BH 65FCC, International Filler, North Tonawanda, NY) was 
used as the base of the placebo. The composition of the placebo is listed in 
Table 8. Magnesium hydroxide powder (USP Grade) was generously 
provided by Watson Foods Co. Inc. (West Haven, Ct). Dextrose corn sugar 
(020010-102, Corn Products International, Bedford Park, IL), fructose (95- 
603, ADM Corn Processing, Decatur, IL), and Now fine ascorbic acid powder 
(0792, Now Foods, Glendale Heights, IL) were purchased from Natural Living 
Center (Bangor, ME). Red (E1248) and violet (E0680) food coloring were 
purchased from Lorann Oils (Ramsey, NJ). Placebo capsules were filled 
using the same methods as the cranberry capsules and were approximately 
the same weight as the cranberry capsules. 
Table 8: Composition of Placebo Powder 






















All blood draws were done at the phlebotomy laboratory at Cutler Health 
Center at the University of Maine, Orono, by Sally Hall, American Society of 
Clinical Pathology (ASCP) Medical Technologist, Amy Kelly, ASCP Medical 
Technologist, and Andy Phellen, ASCP Medical Technologist. The tubes of 
blood were allowed to settle for half an hour before being centrifuged. For 
each patient, one tube of blood was sent to Affiliated Laboratory, Bangor, 
Maine and one tube was taken to Dr Camire's laboratory in Holmes Hall, 
University of Maine. Total cholesterol, triglycerides, LDL, HDL, percent HDL, 
fasting glucose, and HbAlc, levels were analyzed by Affiliated Laboratory, 
insulin levels were analyzed at Associated Regional and University 
Pathologists Inc. (ARUP), and fructosamine levels, aldose reductase activity, 
and hexanal concentration were analyzed by myself at the Holmes Hall 
laboratory. Single values per subject per blood draw were reported by 
Affiliated Laboratory. 
Fasting Blood Glucose 
Fasting blood glucose is a measure of how well the patient's blood glucose 
levels are being controlled at the present time. This analysis is accepted by 
the American Diabetes Association as a standard method to diagnose and to 
monitor treatment of DM. A decrease in blood glucose levels from baseline to 
week 12 for patients in the treatment group would indicate that cranberry 
supplementation had an effect on blood glucose levels. Analysis of fasting 
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glucose was done at Affiliated Laboratory in Bangor, Maine using the oxygen 
electrode method and a Beckman Coulter LX20 Pro clinical system (Fullerton, 
CA) . 
Glycosylated Hemoglobin 
Glycosylated hemoglobin is a useful measure of the effectiveness of 
treatment to control blood glucose levels in the previous 3 months (36). A 
value less than 6% is considered normal. The treatment goal for a person 
with diabetes is to have an HbAlc level less than 7% (1). Levels over 7% have 
been shown to increase incidence of side effects and complications of 
diabetes. This analysis was chosen because a change in HbAlc levels 
between baseline and week 12 in the treatment group would indicate a 
decrease in protein glycosylation with cranberry supplementation. Blood 
analysis of HbAlc levels was completed at Affiliated Laboratory in Bangor, 
Maine using the BioRad Variant II HPLC method. 
Serum Insulin 
Insulin is a hormone necessary for the utilization of carbohydrate. As insulin 
sensitivity decreases in patients with type 2 DM, the body produces more 
insulin in an attempt to control elevated blood glucose levels (2). Some oral 
medications used to treat diabetes increase pancreatic insulin secretion. 
Normal blood insulin levels are 5-35 mmol/L (30 - 210 pmol/L). Blood 
analysis of insulin levels were completed at ARUP (Salt Lake City, Utah) 
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using a chemiluminescent immunoassay. ARUP provided interpretive data 
with the results. 
Cholesterol and Triglyceride Levels 
Diabetes is an independent risk factor for CAD. Elevated total cholesterol, 
LDL cholesterol, and triglyceride levels as well as low levels of HDL 
cholesterol are additional risk factors for coronary artery disease. Patients 
with diabetes have higher total cholesterol, LDL cholesterol, and triglyceride 
levels and lower HDL levels that the general population (19). Due to the 
relationship between diabetes and CAD it is important to control cholesterol 
and triglyceride levels in patients with diabetes. It is especially important to 
control levels of LDL cholesterol because LDL can become glycated with 
elevated blood glucose levels, and these glycated LDL molecules are easily 
oxidized (19). Table 9 shows the 2001 National Heart, Lung and Blood 
Institute recommendations for optimal cholesterol levels. 
Table 9: Recommendations for Cholesterol Levels 







< 150 1.7 
~ 2 0 0  
4 0 0  
40 to 60 
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Serum levels of total cholesterol, triglycerides and HDL were analyzed at 
Affiliated Laboratory utilizing a Beckman Coulter LX20 Pro clinical system and 
time endpoint methodologies. LDL and percent HDL were calculated using 
the results of the total cholesterol and HDL cholesterol (55). The equation 
used to calculate LDL is: 
LDL (mg1dL) = total cholesterol - HDL cholesterol - TG 1 5 
Percent HDL is calculated by the following equation: 
Percent HDL = HDL I total cholesterol * 100 
When total cholesterol level was greater than 200 mg/dL (5.2 mmolIL), direct 
LDL was analyzed using the Beckman Coulter W 0  Pro clinical system and a 
liquid selective detergent method. 
Fructosamine levels are a measure of glycosylated albumin, and are an 
indicator of blood glucose control in the 2 to 3 weeks prior to the test (34). 
Normal values for fructosamine in patients who do not have diabetes are 1.6 
to 2.6 mmol1L. The normal range for patients with diabetes is 2.1 to 5.0 
mmoUL (35) 
Fructosamine Kits (Procedure No.465) were purchased from Sigma 
Diagnostics (St. Louis, MO). A Spectronic 20D+ spectrometer from Spectronic 
Instruments (Rochester, NY) and a heat block (Fisher Scientific Company, 
Fair Lawn, NJ) were used to perform the analysis. Fisher brand micro 
cuvettes (14-385-938) were purchased from Fisher Scientific Company (Fair 
Lawn, NJ). 
The SIGMA Fructosamine Kit (Procedure No.465) was used for analysis of 
serum fructosamine levels. To complete the analysis, the fructosamine 
reagent solution was first heated to 37°C. The spectrophotometer was set to 
a wavelength of 530 nm and the absorbance was zeroed using deionized 
water as a reference. The concentration of the fructosamine calibrator 
solution was recorded from the label on the bottle. Micro-cuvettes were 
numbered allowing for 1 cuvette for the calibrator and enough cuvettes to 
analyze each sample in duplicate. For the calibrator, 1.0 mL of reagent and 
0.1 mL of fructosamine calibrator solution was pipetted into cuvette number 1. 
For each sample, 1.0 mL of reagent solution and 0.1 mL of the appropriate 
serum sample was pipetted into each of the other cuvettes. Each cuvette was 
then mixed by covering with para film and inverting gently. All cuvettes were 
incubated at 37°C for 10 minutes. After exactly 10 minutes the absorbance of 
each cuvette was recorded as initial A. Tube number 1 was recorded as Initial 
A ~ ,  and each of the other cuvettes was recorded as Initial A ~ ~ ~ .  All cuvettes 
were then incubated for exactly 5 more minutes (for a total of 15 minutes) and 
the absorbance of each cuvette was recorded as Final A. Cuvette number 1 
was recorded as Final ACa', and the each of the other cuvettes was recorded 
as Final AteS'. The following calculation was performed for each sample (35): 
Frudosamine (mMoVL) = Final AteS' - Initial AkSt x Concentration 
of 
Final Am' - Initial ACa' Calibrator 
Aldose Reductase Activity 
Sample Preparation 
The method used to analyze aldose reductase activity was derived based on 
a method by Renner et al (56). To perform the deproteinization of the 
samples 100pL of serum, 100pL of 0.69 mM dulcitol (DO-0256 SIGMA 
Chemical Company, St. Louis, MO), and 1mL of absolute ethyl alcohol (200 
proof, 64-1 7-5, Pharmaco Products Inc, Brookfield, CT) was added to a 1.5 
mL centrifuge tube. The dulcitol was used as an internal standard. This 
mixture was vortexed and was then centrifuged using a Beckman Microfuge II 
centrifuge, at 400 XG for 10 minutes. The supernate was collected and the 
precipitate was discarded. The supernate was evaporated under nitrogen until 
dry. Each sample was then derivitized by adding 100pL of 0.49 butyl-boronic 
acid (16, 324-4 Aldrich Chemical Company, Milwaukee, WI) in ethanol to the 
dried sample. The mixture was then mixed in an ultrasonic bath for 10 
minutes. An external standard using 6.86 mM sorbitol (S- 7457 SIGMA 
Chemical Company, St. Louis, MO) instead of serum was mixed and injected 
for each subject using the method described above. 
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Gas Chromatography 
Gas chromatography was performed using a Hewlett Packard HP-6890 gas 
chromatograph (CG) with ChemStation (Agilent. Burlington, MA), using a 
Restek RTXl Crossbond 100% dimethyl polysiloxane 30 m, 0.32mmlD1 0.25 
pm DF CG column (Restek Bellefonte, PA). The software used for GC 
analysis included ChemStation revision A.08.03 (Agilent, Burlington, MA) and 
Teklink 7000 version 2.00 (Tekmar-Dorhman, Cincinnati, OH). Two microliters 
of the prepared sample was injected directly into a Hewlett Packard HP-6890 
CG. Inlet temperature was 250°C with a 100:l split ratio and 9.52 psi and a 
total flow of 195 muminute. The initial oven temperature was 60°C. The 
temperature was increased 45°C per minute to 180°C and held for 1 minute. 
The temperature was then increased by 10°C per minute to 250°C and held 
for 3 minutes. Total run time was 14.67 minutes and equilibration time was 5 
minutes. The retention time of the sorbitol was 13.032, and the retention time 
of the dulcitol was 13.336. Appendix E contains a sample chromatogram from 
the analysis of sorbitol. 
Headspace analysis was performed using a Hewlett Packard HP-6890 CG 
with Chem station software (Agilent, Burlington, MA) and a Tekmar 7000 
Headspace Auto sampler (Tekmar-Dohmann, Cincinnati, OH) using a Restek 
Stabilwax Crossbond Carbowax PEG 30 m, 0.32mmlD1 1.0 pm DF CG 
column (Restek Bellefonte, PA). The software used for headspace analysis 
46 
included ChemStation revision A.08.03 (Agilent, Burlington, MA) and Teklink 
7000 version 2.00 (Tekmar-Dorhman, Cincinnati, OH). Headspace vials, caps 
and teflon septa were purchased from Tekmar-Dorhman (Cincinnati, OH). 
Standards were prepared from hexanal (98% 11 560-6, Aldrich Chemical Co, 
Milwaukee, WI). 
Heads pace 
Rapid headspace gas chromatography (GC) was used to measure hexanal, 
which is a product of lipid peroxidation. Elevated levels of hexanal indicate 
poor antioxidant status and a high level of lipid oxidation. Decreased levels of 
hexanal indicate increased antioxidant status. Hexanal could be used as a 
marker of compliance in this study because the cranberry powder has high 
antioxidant activity. Subjects who consistently take the cranberry capsules 
should have decreasing levels of hexanal during the study. The method used 
was based on work completed by Frankel et al. (57, 58). External standards 
were run each day the samples were analyzed. Five standards were analyzed 
to form a standard curve for analysis and consisted of a 1 mL sample of 50 
pM, 25 pM, 12.5 pM, 6.25 pM and OpM hexanal. For each sample of serum, 1 
mL of serum was placed in a 22 mL headspace vial and sealed. Vials were 
stored in the refrigerator at 4°C until ready to be analyzed. Each sample was 
placed in the carrousel when the previous sample was loaded. Samples were 
held at a temperature of 50°C for 2 minutes. Platen temperature was 100" C, 
platen equilibrium time was 5 minutes, and sample equilibrium time was 10 
minutes. The sample was mixed for 1 minute at a power of 1, and then 
allowed to stabilize for 1 minute. The vial pressurization time was 0.25 
minutes, the pressure equilibrate time was 0.25 minutes, the loop fill time was 
0.25 minutes and the loop equilibrate time was 0.20 minutes. The sample 
loop temperature was 65" C and the line temperature was 65" C. One 
injection was completed per sample and the GC cycle time was 15 minutes. 
Gas Chromatography 
Initial GC temperature was 50°C, and initial time was 2 minutes. The 
temperature was increased 5°C per minute to 65°C. Inlet temperature was 
225°C with a split ratio of 100: 1 and a pressure of 11.9 psi. The run time was 
15 minutes. Split flow was 259.6 mUmin and total flow was 265.4 mL per 
minute. Detector temperature was 180°C with a hydrogen flow of 40.0 mL per 
minute and an air flow of 450 mL per minute. The headspace above a 1 mL 
sample was analyzed for hexanal. SYSTAT 9 (version 9, Chicago, IL) 
statistical software was used to calculate a standard curve using external 
standards discussed previously. The following equation was used to calculate 
the amount of hexanal in each sample: 
mmol of hexanal = (Area of sample * Area of Curve) + constant. 
STATISTICS 
All statistical analysis was completed using SYSTAT analytical software 
(version 9, Chicago IL). The general linear model and Fisher's Least 
Significant Difference test were used for analysis with gender, years since 
diagnosis of DM, initial blood glucose, and age group used as factors. 
Statistical analysis was not completed on information from the health history 
or food frequency questionnaires. 
RESULTS 
SUBJECT DEMOGRAPHICS 
Twelve women and 15 men participated in the Cranberry Diabetes Study. 
There were 14 subjects in the cranberry group and 13 in the placebo group. 
Ages of the subjects ranged from 20 years to 80 years. The mean age of 
subjects in the study was 55 years. Subjects had been diagnosed with DM 
anywhere from 4 months to 408 months prior to participation in the study. 
Only ten of the twenty-seven subjects had initial fasting blood glucose levels 
greater than 7.0 mmol1L (range 4.4 to 13.2 mmol1L). A fasting blood glucose 
level less than 7.0 mmoVL indicates that blood glucose and DM were well 
contmled at the beginning of the study. 
Nine of the subjects were not taking any prescription medications during the 
study. Other subjects were taking antihyperlipidemic, antihypertensive, 
antianxiety, antidepressant and antiarthritic medications. Nineteen of the 
subjects exercised 2 or more times per week, one exercised once per week 
and seven exercised rarely or never. Tables 10 and 11 have complete subject 
demographic information. 
Analysis of the food frequency questionnaires indicated that only three 
subjects consumed 3 servings of fruits and 3 servings of vegetables daily 
(Tables 12 and 13). Average intake of fruit was 1.6 + 1.3 servings per day, 
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Table 12: Cranberry Group Food Frequency Questionnaires 
' Subject Fruit Vege ETOH ( CJ Red Fruit Total Fruit Red Vege Total Vege ' 
CROl 
* Servings /time period Vege = Vegetables, CJ = Cranberry Juice ETOH = Alcoholic beverages 
D = Day W = Week M = Month Y = Year 
2 1 0 1  
Year 
-- -- 
D W D W  
8 40 -- 
D W M Y D W M Y D W M Y D W M Y  
65 - -- - - 14 98 4 -- -- - 6 6 6 
D = Day W = week- M = Month Y = Year 
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and average vegetable intake was 2.8 + 3.7 servings per day. Seventeen of 
the subjects consumed cranberry juice at least once per year (range 0 to 365 
servings per year). The average consumption of cranberry juice was 35 + 98 
servings per year. Ten of the subjects drank alcohol (range 0 to 156 servings 
per year). 
Cranbeny Group 
The cranberry group consisted of six females and eight males (Table 10). 
Ages ranged from 34 to 80 years. The mean age of subjects in the cranberry 
group was 57 years. Eight of the subjects in the cranberry group were over 
the age of 50. Six of the subjects had initial blood glucose levels greater than 
7.0 mmoUL, and eight had normal blood glucose levels. Six of the subjects 
had been diagnosed with DM less than 2 years before the study (range 10 to 
24 months). Two subjects had been diagnosed with DM 2 to 5 years prior to 
participation in the study (both 36 months). The remaining six subjects in the 
cranberry group had been diagnosed with diabetes more than 5 years prior to 
participating in the study (range 65 to 134 months). The mean number of 
months since diagnosis for the cranberry group was 73 + 102 months. Four of 
the subjects in the cranberry group exercised less than once per week, ten 
exercised more than twice per week, and four of the ten who exercised more 
than twice per week exercised 5 or more days per week. 
Four of the subjects in the cranberry group were not taking any prescription 
medications during the study. Eight subjects were taking a diuretic, an 
angiotensin converting enzyme (ACE) inhibitor, or another type of 
antihypertensive drug. Four of the subjects were on cholesterol lowering 
drugs. Six of the subjects in the cranberry group took Advil or aspirin 
regularly. No other over the counter drugs were taken regularly by subjects in 
the cranberry group. Eight subjects in the cranberry group took some form of 
dietary supplement regularly. Participants were asked to refrain from using 
antioxidant supplements for 2 weeks prior to and during the study. Four 
subjects were taking a multivitamin daily, two were taking vitamin C, and two 
were taking vitamin E. Fish oil, vitamin A, calcium, and folic acid were taken 
by one or more subjects. 
The food frequency questionnaires indicated that the majority of patients in 
the study did not eat adequate amounts of fruits and vegetables (Table 12). 
Only one subject in the cranberry group consumed at least 3 servings of fruit 
daily and only four subjects consumed 3 or more servings of vegetables daily. 
Only one subject in the cranberry group consumed 3 servings of fruits and 3 
servings of vegetables per day. 
Placebo Group 
There were six females and seven males in the placebo group (Table1 1). 
Subjects ranged from age 20 to 67. The mean age of subjects in the placebo 
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group was 50 + 58 years. Nine of the subjects in the placebo group were over 
the age of 50. Four of the subjects had initial blood glucose levels greater 
than 7.0 mmoVL. The remaining nine subjects had normal blood glucose 
levels initially. Six of the subjects had been diagnosed with DM less that 2 
years prior to participation in the study (range 4 to 18 months), five had been 
diagnosed 2 to 5 years prior (range 28 to 60 months), and two subjects had 
been diagnosed more than 5 years prior to the study (range 132 to 210 
months). The mean number of months since diagnosis was 50 months. Three 
of the subjects in the placebo group exercised less than twice per week, and 
nine of the subjects exercised more than twice per week, with three of the 
nine exercising 5 or more days per week. 
Five of the subjects in the placebo group were not taking prescription 
medication during the study. Only three subjects in the placebo group were 
taking antihypertensive medications and only two were on cholesterol 
lowering drugs. Four of the subjects in the placebo group took Tylenol or 
aspirin regularly, and one of these subjects took Benadryl regularly. No other 
over-the-counter drugs were taken regularly by subjects in the placebo group. 
Nine of the subjects in the placebo group were taking one or more dietary 
supplements. Prior to the study, six subjects were taking a multivitamin, four 
were taking calcium, two were taking vitamin El and others were taking 
gincoba, chromium, glucosamine, or fish oil supplements. During the study 
these subjects were required to refrain from taking vitamin E and chmmium. 
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Results from the food frequency questionnaires (Table 13) indicated that 
three subjects in the placebo group consumed 3 or more servings of fruit daily 
and four subjects consumed 3 or more servings of vegetables per day. Two of 
these subjects consumed 3 servings of fruit and 3 servings of vegetables per 
day. 
BLOOD ANALYSES 
Fasting Blood Glucose 
There were no statistically significant differences in blood glucose levels 
between the cranberry group and the placebo group when subjects were 
grouped simply by treatment or gender. When subjects were grouped by 
initial blood glucose levels, differences were seen between subjects in the 
cranberry group with initial blood glucose levels greater than 7.0 mmol/L 
compared to patients in the placebo group with initial blood glucose levels 
less than 7.0 mmol/L. There were no significant differences when comparing 
the cranberry group with initial blood glucose levels less than 7.0 mmol/L to 
the placebo group with initial blood glucose levels less than 7.0 mmoVL, or 
when comparing the cranberry group with initial blood glucose levels greater 
than 7.0 mmol/L to the placebo group with initial blood glucose levels greater 
than 7.0 mmoVL. 
When subjects were grouped by years since diagnosis of DM, there was not a 
significant decrease in blood glucose levels from week 0 to week 12 (Table 
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14), but blood glucose levels were significantly lower (p = 0.036) in the 
cranberry group than the placebo group for patients who had been diagnosed 
with DM more than 5 years prior to participating in the study. There were no 
significant differences in blood glucose levels in patients who had been 
diagnosed with DM less than 2 years, or 2 to 5 years prior to participation in 
the study. 
Table 14: Mean Fasting Glucose Levels by Years since Diagnosisa 
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In patients less than 50 years of age, serum glucose levels decreased 
significantly (p = 0.030) in the cranberry group compared to the placebo group 
at week 6 (Table 15). This was not the case at week 12. Serum glucose 
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levels decreased 7% in the cranberry group and increased 33% in the 
placebo group at week 6 in subjects less than 50 years of age. 
In patients older than 50 years, there were no significant differences between 
the cranberry group and the placebo group either at week 6 or at week 12. 
Mean serum glucose level decreased 0.5 mmol/L between week 0 and week 
12 in the cranberry group and 0.3 mmol/L in the placebo group. 







There were no significant differences in HbAlc levels when subjects were 
grouped by treatment, gender, age group, or initial blood glucose levels. 
Mean HbAlc decreased slightly in women in both the cranberry group and the 
placebo group from week 0 to week 6 (Table 16). Both groups increased from 
60 
Age Group 
a mmol/L, 1 reading per person per time 
' Significant difference (p = 0.030) in blood glucose levels from week 0 to week 6 
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6.7 + 1.5 
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12 
6.9 + 1.1 
8 .3+ 1.8 
6.3 k 1.5 
6.1 f 1.2 
week 6 to week 12. In males, mean HbAlc decreased in the cranberry group 
between week 0 and week 6 and returned to the week 0 value at week 12. In 
the placebo group, the mean was the same at week 6 as at week 0, but 
increased from week 6 to week 92. From week 0 to week 12 there was a 
difference bordering on significance (p = 0.060) for males between the 
cranberry group and the placebo group. 
Table 16: Mean HbAtc Levels by Gendep 
No significant differences between cranberry and placebo when subjects grouped by gender. 
Difference bordering on significance (p = 0.060) for males at week 12 between treatments. 
When subjects were grouped by years since diagnosis (Table 17), HbAlc 
levels decreased in the cranberry group from week 0 to week 6 (-0.3), and 
increased in the placebo group (+0.2) in subjects who had been diagnosed 
with DM more than 5 years prior to the study. HbAlc levels decreased 
significantly (p = 0.031) in the cranberry group compared to the placebo group 
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Both the cranberry group and the placebo group either had returned to week 
0 values or had a slight increase in mean HbAlc levels at week 12 regardless 
of time since diagnosis. 
Table 17: Mean HbAqc Levels by Years since Diagnosisa 
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There were no statistically significant differences in fructosamine levels from 
week 0 to week 12 between the cranberry group and the placebo group when 
data was analyzed for treatment effects, gender effects, time since diagnosis, 
or initial blood glucose levels, but subject age was influential. 
5 
6.2% + 0.8 
5.9% f 0.3 
6.3% + 0.7 
2 
6.1% + 0.8 
6.0% + 0.2 
6.5% + 0.9 
6.6% + 1.8 6.3% + 1.4* 
7.2% + 0.2 7.4% + 0.6* 
Fructosamine levels improved significantly (p = 0.027) in the cranberry group 
compared to the placebo group in patients less than the age of 50 from week 
0 to week 6, but increased in the cranberry group from week 6 to week 12 
(Table 18). There was not a statistically significant difference in fructosamine 
levels from week 0 to week 12 in either the group under the age of 50 or the 
group over the age of 50. 












~ignifi&ntl~ (p =0.027).lower in cranberry group compared to placebo group at week 6. 
No significant differences from week 0 to week 12. 
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I 
Aldose Reductase Activity 
>50 
>SO 
GC analysis of serum sorbitol measured sorbitol in only 6 serum samples, 
8 
9 
and all were in the week 0 blood draw. Each sample was measured using 2 
duplicates and 2 replicates of each duplicate. Results were not consistent 
since none of the results indicated that there was sorbitol in both duplicates 
and both replicates. Table 19 has detail of results of sorbiiol analysis. 
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Table 19: Aldose Reductase Activity Resultsa 
D Indicates Duplicate R Indicates Replicate 










There were no statistically significant differences in serum insulin levels 
between the cranberry group and the placebo group when subjects were 
grouped by treatment, gender, initial blood glucose level, or age group. There 
were statistically significant differences in serum insulin levels when patients 
were grouped by time since diagnosis of DM. 








When subjects were grouped by time since diagnosis of DM, there was an 
overall statistically significant difference (p = 0.015) in serum insulin levels 
Sorbitol 
between the treatment group and the placebo group at week 12 (Table 20). At 
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week 12, serum insulin levels in patients in the placebo group with diabetes 
more than 5 years were significantly higher than in any other group. In the 
group that had DM greater than 5 years, serum insulin levels decreased 
significantly (p = 0.002) in the cranbeny group compared to the placebo 
group. 








' prnok, 1 reading per person per time 
Overall significant decrease (p = 0.01 5) in cranbeny group compared to placebo group. 
' Cranbeny group decreased significantly (p = 0.002) compared to placebo group 
" Significantly higher than any other group. 
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There were no statistically significant differences in serum triglycerides, total 
cholesterol, LDL, HDL or percent HDL between the cranberry group and the 
placebo group when patients were grouped by treatment, gender, initial blood 
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glucose, or age group. There were significant differences in lipid levels 
between the cranberry group and the placebo group when subjects were 
grouped by time since diagnosis. Table 21 lists mean lipid levels by 
treatment. 
Table 21 : Mean Lipid Levelsa 
Triglycerides 
a 
Triglycerides were significantly lower (p = 0.01 1) in the cranberry group than . 
the placebo when subjects were grouped by years since diagnosis of DM 
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more than 5 years. Among patients with DM more than 5 years, triglyceride 
levels decreased significantly (p = 0.002) from week 0 to week 12 in the 
cranberry group compared to the placebo group. Triglyceride levels 
decreased 16% in the cranberry group and increased 152% in the placebo 
group. In the group with DM more than 5 years, triglyceride values decreased 
significantly (p = 0.013) in the cranberry group compared to the placebo 
group. 
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I 
IQ per person per time 
- .  . 
Overall cranbeny group decr&sed significantly (p = 0.01 1) compared to the placebo group 
from week 0 to week 12. 
' Decreased significantly (p = 0.002) in the cranbeny group compared to the placebo group. 
" Significantly higher than any other group. 
Total Cholesterol 
Total cholesterol levels decreased significantly (p = 0.034) from week 0 to 
week 12 in the cranberry gmup compared to the placebo group when 
subjects were grouped by years since diagnosis of DM (Table 23). Subjects in 
the placebo group that had been diagnosed with DM over 5 years ago had 
significantly higher cholesterol levels than any other group at week 12. In 
subjects with DM over 5 years, cholesterol levels improved significantly (p = 
0.007) in the cranberry group compared to the placebo group. 











a mmolIL, 1 reading per person per time 
Overall cranberry group significantly (p = 0.034) lower than placebo group. 
Decreased significantly (p = 0.007) in the cranberry group compared to the placebo group. 
" Significantly higher than any other group. 
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Percent HDL Cholesterol 
From week 0 to week 12, percent HDL improved significantly (p = 0.021) in 
the cranberry group compared to the placebo group in subjects who had DM 
more than 5 years (Table 24). There were no statistically significant 
differences in percent HDL between the cranberry group and the placebo 
group in patients that had been diagnosed with DM 0 to 2 or 2 to 5 years prior 
to the study. 
Table 24: Mean Percent HDL Levels by Years since Diagnosisa 
'~reatment Years Since N Time (Weeks) 
/ Diagnosis I Cranberry 1 0 - 2 
Placebo 
Placebo 2 - 5  
I Placebo I >5 
1 reading per person per time 
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ranbeny group compared to the placebo group. 
The results of analysis of serum hexanal were not sufficient to draw any 
conclusions. Six subjects in the cranberry group and 2 subjects in the placebo 
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group had measurable serum hexanal levels at one of the 3 blood draws. 
None of the subjects had measurable levels of serum hexanal at more than 
one of the blood draws. Table 25 contains the results of the hexanal analysis. 
Table 25: Hexanal Resultsa 
Subject Draw Treatment Hexanal (mmol) 
- 
CROl 1 Cranberry 1.512 
CR02 
Cranberry 
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a Data insufficient to draw conclusions 
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DISCUSSION 
HUMAN SUBJECTS 
Recruiting, Scheduling, and Compliance 
The most challenging aspect of this study was working with human subjects. 
Recruiting, scheduling, and compliance were all important issues in carrying 
out this investigation. Many of the people who replied to the recruitment ads 
were not eligible for the study due to medical complications or use of 
hypoglycemic medications. A large hospital in the area was recruiting for a 
similar study at the same time, so it was difficult to find eligible subjects. The 
fact that blood could be drawn only at Cutler Health Center on the University 
of Maine campus also affected recruiting. Several participants had to travel 
from rural areas of Maine to participate in the study, while others decided not 
to participate due to the need to travel. In the end, the number of subjects 
was three short of the goal of thirty subjects. 
Scheduling was also challenging for several reasons. It was necessary to 
schedule blood draws on days that were convenient for the staff at the 
phlebotomy lab. Whenever possible several subjects were scheduled to have 
blood drawn on the same day, so it was necessary to schedule extra staff at 
the phlebotomy lab. Most of the subjects were employed, so it was necessary 
to schedule blood draws around their work schedules. The subjects also 
needed to fast for 12 hours prior to the blood draw, so blood draws were 
scheduled in the mornings. 
Compliance may have been an issue in this study. Subjects were called or 
emailed periodically to remind them to take the capsules, but there was no 
method in place to ensure that subjects took the capsules. Hexanal could 
have been used as a marker of compliance due to its high antioxidant activity; 
however, the results were not sufficient to draw conclusions. Unused 
capsules were not returned at the conclusion of the study, which would have 
been one measure of subject compliance. Several of the subjects had 
improvements in laboratory values at the week 6 blood draw, but did not 
sustain the improvements at week 12. This could be due to decreased 
compliance during the last 6 weeks of the study, or due to other unknown 
factors. 
Subject Demographics 
Differences between the subjects on the cranberry treatment and the subjects 
on the placebo may have affected the results of this study. Subjects were 
randomly assigned to either the cranberry group or the placebo group, and 
the demographics of each group were very different. The results might have 
been different if subjects had been matched between the cranberry group and 
the placebo group instead of randomly assigned to a group. If the two groups 
had been more similar, it is likely we would have seen more significant 
results. 
Patients in the placebo group were likely healthier overall than patients in the 
cranberry group. Overall the patients in the placebo group were younger and 
had been diagnosed with DM more recently than subjects in the cranberry 
group. The mean age of the placebo group was 4 years younger than the 
cranberry group, but the number of subjects over the age of 50 was 
comparable in both groups (8 cranberry, 9 placebo). The mean number of 
months since diagnosis was 23 months less in the placebo group than in the 
cranberry group. There were six subjects in each group that had been 
diagnosed with DM less than 2 years prior to participation in the study, but the 
cranberry group had five subjects who had DM for more than 5 years, 
compared to only two in the placebo group. Since DM is a progressive 
disease, it is likely that patients who have had DM longer will have more 
complications from the disease, and they may be less healthy. The subjects 
who have had DM for a shorter time are likely to have lower values on 
laboratory analyses than subjects who have had the disease longer, and lab 
values are more likely to be stable throughout the study. 
There were fewer subjects in the placebo group with elevated blood glucose 
levels initially than in the cranberry group. Six subjects in the cranberry group 
had elevated blood glucose levels at week 0 compared to four in the placebo 
group. It is likely that cranberry supplementation will have more of an effect 
for patients with elevated blood glucose levels, but because a larger number 
of subjects in the placebo group had normal blood glucose levels, statistical 
significance may be difficult to see. 
There were fewer subjects in the placebo group taking prescription 
medications. Eight subjects in the cranberry group were being treated for high 
blood pressure compared to three in the placebo group. Four subjects in the 
cranberry group were taking medication for high cholesterol compared to two 
in the placebo group. This may be due to the increase risk of macrovascular 
complications associated with DM. The higher number of subjects with 
hypertension and hyperlipidemia in the cranberry group may have been 
related to the number of subjects who had DM for a longer period. 
Intake of fruits and vegetables was poor in both groups. One subject in the 
cranberry group and two in the placebo group consumed 3 servings of fruits 
and 3 servings of vegetables per day. One subject in the cranberry group 
compared to three in the placebo group consumed 3 servings of fruit per day, 
and four subjects in each group consumed 3 servings of vegetables per day. 
Serving sizes on the food frequency questionnaire were larger than those 
used in diabetic carbohydrate counting and the Food Guide Pyramid, so use 
of a different measure may have resulted in improved fruit and vegetable 
intakes. 
Three subjects in the cranberry group consumed cranberry juice occasionally, 
compared to seven in the placebo group. There was little consumption of red 
colored fruits and vegetables in either group. The red fruits and vegetables 
have anthocyanin and flavonoid contents similar to cranberries. Subjects that 
normally have a high intake of cranberry juice and other fruits and vegetables 
that contain anthocyanins and flavonoids may have seen less benefit in this 
study due to the fact that they were already consuming a beneficial diet. 
A very diverse group of subjects participated in this study. The wide range of 
initial blood glucose values and levels of control of the disease may have 
affected the ability to see statistical significance when analyzing data. If all 
subjects had elevated blood glucose levels at the beginning of the study, the 
effect of cranberry supplementation may have been more significant. 
INDICATORS OF CONTROL OF DIABETES MELLITUS 
ACdose Reductase ActiiCty 
The method used to analyze sorbitol in serum samples as an indicator of 
aldose reductase activity was not sufficiently sensitive. It is likely that more 
subjects had sorbitol present in their serum than was measured: All samples 
that had measurable sorbitol were in the week 0 blood draw, and results were 
not consistent between duplicates and replicates. It is not likely that sorbitol 
decreased in the placebo group from week 0 to week 12, especially in 
subjects whose blood glucose levels and HbAlc levels increased. Some 
chromatograms showed small peaks at the sorbitol retention time, but the 
peaks were too small to measure. Use of a different method or refinement of 
the current method would have resulted in more precise measurement of 
sorbitol in the serum samples. High concentrations of sorbitol are not normally 
present in the serum, so it is not surprising that the results were insufficient. If 
red blood cells had been used to analyze sorbitol instead of serum, the 
results would likely have been more significant. 
Glucose, HbAIC, Fructosamine, and Insulin Levels 
In most of the analyses performed as indicators of DM control, significant 
differences were seen only when data was grouped by length of time since 
diagnosis of DM and only in the group that had the disease the longest. More 
pronounced results are likely to be seen with cranberry supplementation in 
individuals who have had the disease the longest because they may have the 
higher glucose levels that result in more damage from hyperglycemia. The 
higher glucose levels would lead to protein glycosylation. 
Grouped by Treatment and Gender 
There were no significant differences in blood glucose, HbAlc, fructosamine, 
or insulin levels when subjects were grouped simply by treatment or when 
they were grouped by gender. This is likely due to the fact that many of the 
subjects already had good control of their DM at the beginning of the study. 
Seventeen subjects (63%) had normal blood glucose levels initially. When 
glucose levels are in the normal range, it is less likely that an improvement 
will be seen. If the initial screening process had excluded subjects with 
normal fasting blood glucose levels, it is likely that cranberry supplementation 
would have shown more benefit overall. 
As discussed earlier, protein glycoslylation occurs in relation to the level of 
hyperglycemia, so subjects with good control of DM have less glycosylation of 
protein. This would affect results of the HbAlc and fructosamine analyses. 
Only two subjects in the cranberry group and three in the placebo group had 
HbAlc levels greater than 7% initially. One in each group had HbAlc levels 
greater than 9%. With subjects with well controlled DM, there is little 
opportunity for improvement in laboratory values. 
DM may affect insulin levels in two ways. As discussed earlier, type 2 DM 
may be due to decreased pancreatic production of insulin, decreased insulin 
sensitivity in the cells of the body, or a combination of both problems. In 
subjects with decreased insulin production, serum insulin levels decline as the 
disease progresses. In subjects with decreased insulin sensitivity, insulin 
levels increase as the disease progresses. Most subjects in this study had 
normal insulin levels throughout the study. Only two subjects had elevated 
insulin levels at week 0, four had elevated insulin levels at week 6, and only 
one subject had elevated insulin levels at week 12. The high number of 
subjects with normal insulin levels suggests that there would be little 
improvement in insulin levels especially when subjects are grouped by 
treatment or by treatment and gender. 
The diversity of the subjects is also a factor when analyzing data. The age 
range of subjects and the variability of control of glucose levels decreased 
likelihood of seeing significant differences when subjects were grouped 
simply by treatment or by treatment and gender. 
Grouped by Years since Diagnosis 
Most statistical significance in data analysis was seen when subjects were 
grouped by time since diagnosis. Blood glucose levels and insulin levels were 
significantly higher at week 12 in subjects in the placebo group who had DM 
more than 5 years. This is to be expected because DM is a progressive 
disease. The longer a person has DM, the higher the degree of insulin 
insensitivity. As insulin sensitivity decreases, the body must produce more 
insulin to control blood glucose levels. Eventually the pancreas is unable to 
produce enough insulin to control glucose levels, and oral hypoglycemic 
drugs or exogenous insulin becomes necessary. 
When subjects were grouped by years since diagnosis of DM, HbAic levels 
decreased significantly in the cranberry group compared to the placebo group 
at week 6 in the group that had DM the longest. Mean HbAlc levels were 
highest in the placebo group that had DM more than 5 years. The longer a 
person has DM, the more likely that elevated glucose levels will cause protein 
glycosylation and the subsequent damage. This is the group that will benefit 
most from inhibition of aldose reductase and non-enzymatic protein 
glycosylation. 
The fact that HbAlc levels decreased at week 6 and then increased at week 
12 may have been due to decreased compliance in the last 6 weeks of the 
study or it may have been due to a degradation of anthocyanins in the 
cranberry powder as the study progressed. It is not known how the 
processing of the cranberry powder used in this study affected the 
anthocyanins and flavonoids. It would have been beneficial to measure the 
anthocyanin and flavonoid content of the cranberry powder at the beginning 
of the study and again at the end of the study. This would be an indication of 
whether the changes seen from week 6 to week 12 were due to degradation 
of anthocyanins and flavonoids. 
As with other indicators of severity and control of DM, significant differences 
in insulin levels were found only when subjects were grouped by time since 
diagnosis of DM. There was an overall significant difference in insulin levels, 
with subjects in the placebo group that had DM the longest having 
significantly higher insulin levels than any other group. This is expected due 
to the increase in insulin sensitivity as the disease progresses. It should be 
noted that there was a wide range of insulin levels and the standard 
deviations were extremely high. A few subjects had highly elevated insulin 
levels. 
Another important factor in analyzing data when subjects were grouped by 
years since diagnosis is that there were only two subjects in the placebo 
group with DM more than 5 years. One of the subjects in this group had near 
normal glucose and HbAlc levels initially (5.8 and 7.3 respectively) but had 
large increases from week 0 to week 6 (glucose 5.8 to 7.1 and HbAlc 7.3 to 
7.8), and from week 6 to week 12 (glucose 7.1 to 9.5 and HbAlc 7.8 to 8.7). 
The other subject in this group had initial glucose and HbAlc values in the 
desirable range and decreased by week 12. The small number of subjects in 
this group and the diversity in the control of the disease may have influenced 
results of the study. 
Grouped by Initial Glucose Levels 
When subjects were grouped by initial glucose levels, differences were seen 
in glucose levels at week 12. Glucose levels were significantly lower in 
cranberry subjects with initial glucose levels greater than 7.0 mmolIL, than in 
the placebo group with initial glucose levels less than 7.0 mmol1L. This is 
likely due to the fact that subjects with elevated glucose levels are more likely 
to see improvement in these values, while subjects with normal glucose levels 
remain stable. 
Grouped by Age 
One might think that blood glucose, HbAlc, fructosamine and insulin levels 
would be higher in older subjects, but that was not the case in this group of 
subjects. Mean glucose levels were not significantly higher in the group of 
subjects older than 50 years. This could be due to the fact that only three 
subjects over the age of 50 had DM for more than 5 years, and five subjects 
under the age of 50 had DM for more than 5 years. Results of this study 
indicated that age did not influence the effect of cranberry supplementation on 
glucose levels, but time since diagnosis did. This is likely due to the fact that 
the subjects who had DM the longest were not necessarily the oldest 
participants. 
Hexanal 
Headspace analysis of hexanal concentration of serum samples was used to 
measure lipid oxidation and antioxidant status with cranberry 
supplementation. The method was not effective in this study. It is possible 
that if there had been another standard at a lower concentration (3.125 pM), 
more subjects would have had detectable amounts of hexanal measured in 
their serum. Due to the poor outcomes of this analysis, the effect of cranberry 
supplementation on oxidant status and lipid oxidation is unknown. 
Triglycerides, Total Cholesterol, LDL, HDL and Percent HDL 
Significant differences were seen in lipid levels only when subjects were 
grouped by time since diagnosis of DM, and then only in triglyceride levels, 
total cholesterol, and percent HDL. In all cases the differences were seen in 
the group who had DM for more than 5 years. Subjects in the placebo group 
who had the disease more than 5 years had higher lipid levels than any of the 
other groups. Mean triglyceride and total cholesterol levels were stable from 
week 0 to week 12 in all groups except those with DM more than 5 years. In 
this group the mean values decreased for subjects on the cranberry treatment 
and increased for subjects on the placebo treatment. 
The changes in triglyceride levels are likely due to the correlation between 
hyperglycemia and elevated triglycerides. As blood glucose levels increase, 
triglyceride levels increase proportionately. As discussed previously, one of 
the two subjects in the placebo group with DM for more than 5 years had 
significant increases in glucose levels during the 12 week study. It is likely 
that the hyperglycemia resulted in the elevated triglyceride levels. 
Changes in percent HDL were likely a result of changes in total cholesterol 
levels. Percent HDL is calculated by dividing HDL by total cholesterol and 
multiplying by 100, so a change in total cholesterol will impact percent HDL 
independent of changes in HDL levels. 
PREVIOUS WORK 
There have not been any previous in vivo studies investigating cranberry 
supplementation to decrease the side effects of DM in humans. The results of 
this study correspond with research previously done in rats and in vitro, 
investigating the effect of supplementation of anthocyanins and flavonoids on 
diabetes. Jankowiski et al. (45) investigated the effects of anthocyanin 
pigments from red wine on blood and urine glucose levels in 80 rats. There 
was a decrease in glucose concentrations with supplementation of 
anthocyanins. In the current study, there was a decrease in blood glucose 
levels in patients on the cranbeny treatment who had DM the longest and 
who had elevated blood glucose levels initially. 
Keenoy and De Leeuw (44) investigated the effect of a flavonoid preparation 
on protein glycosylation and antioxidant status in twenty-eight subjects with 
type 1 DM in a three month study. There was a significant decrease in HbAlc 
levels with flavonoid treatment. In the current study, HbAlc levels decreased 
in the group of subjects who had DM over 5 years and in the group with 
elevated glucose levels initially. Daflon 500, the flavonoid preparation used in 
the Keenoy and Le Leeuw study, contains a much higher concentration of 
flavonoids than cranbeny juice. Due to the lower concentration of flavonoids 
in cranbeny juice, a higher dosage would likely be needed to see the same 
effects. If a higher dosage of cranberry juice had been used in the current 
study, this might have resulted in significant differences overall between the 
cranberry group and the placebo group. 
Hamada et al. (40) investigated the effect of epalrestat, a known aldose 
reductase inhibitor, in subjects with type 2 DM who had been taking the drug 
for 2 months. There were decreases in the end products of protein 
glycosylation (sorbitol, fructose, triosephosphats, TBARS and 3-DG levels), 
but no changes in plasma glucose or HbAlc levels. In the current study, there 
were decreases in glucose and HbAlc levels in subgroups of the subjects, but 
end products of protein glycosylation were not measured, and analysis of 
sorbitol was unsuccessful. 
Pedersen et al. (52) conducted a study comparing the antioxidant capacity of 
consumption of cranberry and blueberry juice in the plasma of nine female 
volunteers. Results indicated that consumption of blueberry juice did not 
significantly increase plasma concentrations of total phenols or vitamin C as 
cranberries did, though bluebemes have a higher concentration of phenolic 
substances than do cranbemes. Cranberry juice is fortified with vitamin C and 
the blueberry juice used in this study was not. Researchers question how 
readily the phenols were absorbed in the gut. Consumption of cranberry juice 
did lead to significant increases in total phenols and a 30% increase in serum 
vitamin C concentration. It is possible that increases of total phenols in serum 
following cranberry juice consumption was primarily due to the increased 
vitamin C levels. If anthocyanins are not readily absorbed, then it is possible 
that the dosage used in the Cranberry Diabetes Study was insufficient to see 
significant results. It is likely that a higher intake of cranberry juice would have 
resulted in more significant differences. 
The form of cranberry juice may also have been a factor in the results of this 
study. The processing of the Decas cranberry powder may have decreased 
the anthocyanin content of the product. Liquid cranberry juice was used in 
Pederson's study, which may have contained more anthocyanins and 
flavonoids than the powder that had additional processing. The heat used in 
processing the cranberry juice into powder may have caused degradation of 
the anthocyanins and other flavonoids in the juice. This would decrease the 
antioxidant activity of the powdered juice. 
A study conducted by Vincent et al. (38) investigated the ability of vitamin C to 
inhibit aldose reductase in human erythrocytes. Results indicated that 
ascorbic acid decreased intracellular sorbitol concentrations by 25 to 45 %. 
Vitamin C may be beneficial for people with diabetes, and most commercial 
cranberry juice cocktail has high levels of vitamin C. Many of the subjects in 
the placebo group did not consume fruits and vegetables high in vitamin C. 
Subjects who did not consume adequate vitamin C might have benefited from 
the small amount of vitamin C in the placebo, which would have masked the 
effects seen for patients on the cranberry treatment. 
CONCLUSIONS 
The results of this study suggest that cranberry supplementation may be 
beneficial for patients with type 2 DM who have poor control of glucose levels, 
but further research must be conducted. The subjects in the cranberry group 
were very different than in the placebo group. Differences in age, control of 
DM, and time since diagnosis between the placebo group and the cranberry 
group likely affected the results of this study. The number of subjects with 
normal blood glucose and HbAic levels was likely also a factor in the results 
of this study. 
The form of cranberry juice may have affected the results of this study as 
well. It is unknown how the bioavailability of the spray dried cranberry powder 
used in the study compares to commercial cranberry juice cocktail. The 
processing method used for the Decas cranberry powder may have affected 
the anthocyanin and flavonoid content of the product. It is possible that using 
liquid cranberry juice or raw cranberries might have produced different 
results. The anthocyanins in the cranberry powder may also have degraded 
throughout the course of the study. This would explain the decreases in 
laboratory values at week 6 and the increases at week 12. 
There is a need for further research in this area. Future research should focus 
on subjects with hyperglycemia, because these are the subjects that are likely 
to have more of the side effects that are associated with DM. It is also 
important to investigate the correct dose of cranberry juice. In this study all 
subjects received the same dose regardless of body weight, but people with a 
larger body mass would need a higher dosage than smaller individuals to see 
effects of cranberry supplementation. Investigation of how supplementation 
with whole cranberries or cranberry juice differs from supplementation with 
juice or powders is also important because processing may affect the 
anthocyanins found in cranberries. 
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Information About Study: 
I am invited to participate in a research study entitled 'Can Cranberry 
Supplementation Reduce Risks for Diabetes?" conducted by Dr. Mary Ellen 
Camire and Belinda Chambers at the University of Maine Department of Food 
Science and Human Nutrition. This preliminary study is designed to investigate 
the potential health benefits of cranberry juice for people with Type 2 diabetes. 
The study is one in which there will be two treatment groups. One group will be 
taking cranbeny capsules and one group will be taking a placebo or control. Only 
the primary investigator will know who is taking the cranbeny capsules and who 
is taking the placebo. This study is sponsored by the Cranbeny Institute and the 
Wisconsin Cranbeny Board. 
Procedure: 
I have been asked to consume six capsules each day for 12 weeks. I will need to 
take two capsules in the morning, two capsules midday and two capsules with 
my evening meal. Each capsule contains 0.123 grams of sugar. The gelatin 
capsules contain either spray dried cranbeny juice powder made with 
magnesium hydroxide, (from Decas Cranbeny Products Inc.) or a placebo 
containing cellulose, ascorbic acid, fructose, sucrose magnesium hydroxide and 
food coloring. The capsules are made from gelatin; I do not have a dietary 
aversion to eating gelatin. If I have difficulty swallowing the capsules, I can open 
the capsules, dissolve the powder in water, and drink the mixture, or I can mix 
97 
the powder with yogurt or another food and eat it that way. As part of the study I 
will be asked to complete a health history and a food frequency questionnaire. 
This questionnaire will contain questions such as "When were you diagnosed 
with diabetes?" and "Did (do) your siblings have Type 2 diabetes?" and "How 
many servings of fruits and vegetables do you eat each dap"  I should 
discontinue use of all vitamin supplements(vitamin El vitamin C, chromium, etc.) 
except a multivitamin, at least two weeks prior to the start of the study. I should 
not change my normal consumption of blueberries, cranberries and grapes 
during the course of study. A sample of my blood will be drawn at the beginning 
of the study and again at the sixth week and the twelfth week of the study. 
I am at least 18 years old, I am not pregnant, and I am not taking medication for 
diabetes, autoimmune, heart, liver or kidney disease. I have Type 2 diabetes and 
am controlling my blood sugar with diet alone. My participation in the study is 
voluntary. Either myself or the primary investigator may terminate the study at 
any time. The supplements that will be given to me are food products. The blood 
collection process is no different from one I would experience in a doctor's office 
or a hospital laboratory. 
Risks 8 Benefits: 
There may be some minor bruising from the blood drawing procedure, but the 
risk is no different from any other blood drawing procedure. I will be given $1 50 
for my participation in the study, $50 for each blood drawing procedure. I may 
receive copies of my lab results if I so desire. I may also have some immediate 
health benefits such as decreased oxidation of LDL cholesterol, decreased 
retinopathy, nephropathy and neuropathy. 
Confidentialitv: 
All information and data that are collected in this research project will be kept 
confidential and locked in the investigator's office. A number code will be used on 
all records and results to ensure confidentiality. Once the final manuscript has 
been published, all confidential records will be destroyed. All records and 
personal information about my involvement in this project will be kept 
confidential, and my name will in no way be associated with the results of this 
project. The results of this project will be released in summary form only. 
Contact Information: 
If I have any questions I can reach Dr. Mary Ellen Camire or Belinda Chambers 










A .  At what age were you diagnosed with Type 2 diabetes? 
2. How long have you had Type 2 Diabetes? Years Months 
3. Are you taking medication for your diabetes? Yes 
No 
4. Are you taking any prescription medications? Yes No 
If yes, what are you taking? 
5. Are you taking any over the counter medications? Yes 
No 
If yes, what are you taking? 
6. Are you taking any dietary supplements? 
If yes please list: 
Yes No 
7. How often do you exercise? 
8. What types of exercise do you perform? 
9. During the next 12 weeks, do you plan to begin an exercise program or 
increase the amount of exercise you do? 
Yes No 
10. Do any of your family members have diabetes? 
Mother Yes No 
Father Yes No 
Grandmother Yes No 
Grandfather Yes No 
Siblings Yes No 
APPENDIX C 
Food Frequency Questionnaire 
1. How many W cup servings of fruit do you eat each day3 each week? 
2. How many W cup servings of vegetables do you eat each day3 each week? 
4. How many times each day, week, month or year do you eat the following fruits? 
Place a number in the correct column to indicate how often you eat the listed 
3. Do you drink alcohol? Yes No 
If yes, how many servings of alcohol do you drink daily, weekly monthly or 
yearly3 
Place a number in the column to indicate how often you drink the alcoholic 











































5. How many times each day, week, month, year do you eat the following 
vegetables? 
Place a number in the correct column to indicate how often you eat the listed 






















I Sweet peppers 
Other 









Figure D-I: HPLC Chromatogram 
APPENDIX E 
Figure E-1: Sorbitol Chromatogram 
-- -- 
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